Search research articles
Contact Us
Filters
Showing results (451-460 of 567) with videos related to
Page
of 57
Sort By:
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Andre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Genes and Immunity
|
October 16, 2004
The EIF2AK3 gene region and type I diabetes in subjects from South India
R A Allotey, V Mohan, M F McDermott, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2019
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry
M Fishman, J P Dutcher, J I Clark, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K Erbe, Wei Wang, Jacob Goldberg, et al.
Page
of 57
Search research articles
Search
Showing results (451-460 of 567) with videos related to
Sort By:
Page
of 57
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 14, 2016
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Andre P Fay, Guillermo de Velasco, Thai H Ho, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal for Immunotherapy of Cancer
|
March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2017
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J Hammers, Elizabeth R Plimack, Jeffrey R Infante, et al.
Genes and Immunity
|
October 16, 2004
The EIF2AK3 gene region and type I diabetes in subjects from South India
R A Allotey, V Mohan, M F McDermott, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2019
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry
M Fishman, J P Dutcher, J I Clark, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K Erbe, Wei Wang, Jacob Goldberg, et al.
Page
of 57